Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.73 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.73 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.73 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.72 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.68 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.68 |
| ▸ | AMD1 | P17707 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MARS1 | P56192 | 1/20 | 0.51 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 2/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.50 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.50 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407241 | 1.00 | PI4KA (0.73) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL30544933 | 1.00 | PI4KA (0.73) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL11889816 | 0.96 | PI4KA (0.80) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL19859400 | 0.92 | PI4KA (0.76) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL5672241 | 0.92 | PI4KA (0.73) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL16579246 | 0.89 | RXFP1 (0.58) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL12800890 | 0.89 | PI4KA (0.68) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL1796855 | 0.89 | RXFP1 (0.57) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL1798145 | 0.89 | RXFP1 (0.57) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL5317973 | 0.89 | RXFP1 (0.57) | PI4KAPI4K2BPI4K2API4KBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| EP-2204154-B1 | Association of monosaccharides and adenosine and its cosmetic use | ORÉAL L (FR) | 2016-10-12 | — | — | EP | disclosed |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARM INC (US) | 2016-07-07 | — | — | US | disclosed |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-1848718-B1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARM INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1878470-A1 | Skin depigmentation method | L'Oréal (FR) | 2008-01-16 | — | — | EP | disclosed |
| US-20070258921-A1 | PROCESS FOR DEPIGMENTING THE SKIN | L'OREAL (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070258921-A1 | PROCESS FOR DEPIGMENTING THE SKIN | L'OREAL (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070258921-A1 | PROCESS FOR DEPIGMENTING THE SKIN | L'OREAL (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1847547-A1 | Anti-wrinkle cosmetic composition | L'Oréal (FR) | 2007-10-24 | — | — | EP | disclosed |
| EP-1847547-A1 | Anti-wrinkle cosmetic composition | L'Oréal (FR) | 2007-10-24 | — | — | EP | disclosed |
| US-20070237734-A1 | ANTI-WRINKLE COSMETIC COMPOSITION | L'OREAL (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20070237734-A1 | ANTI-WRINKLE COSMETIC COMPOSITION | L'OREAL (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20070237734-A1 | ANTI-WRINKLE COSMETIC COMPOSITION | L'OREAL (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | PI4KA 1455/4885PI4K2B 2027/4885PI4K2A 1655/4885 |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | PI4KA 1455/4885PI4K2B 2027/4885PI4K2A 1655/4885 |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | PI4KA 1991/4885PI4K2B 2891/4885PI4K2A 2431/4885 |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | PI4KA 1546/4885PI4K2B 704/4885PI4K2A 804/4885 |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | PI4KA 1455/4885PI4K2B 2027/4885PI4K2A 1655/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | PI4KA 1991/4885PI4K2B 2891/4885PI4K2A 2431/4885 |
| US-20070258921-A1 | PROCESS FOR DEPIGMENTING THE SKIN | TYR, CUTA, NQO1 | PI4KA 3626/4885PI4K2B 3652/4885PI4K2A 3111/4885 |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | PI4KA 1546/4885PI4K2B 704/4885PI4K2A 804/4885 |
| US-20070237734-A1 | ANTI-WRINKLE COSMETIC COMPOSITION | ADORA2A, ADORA3, ADORA1 | PI4KA 1477/4885PI4K2B 1481/4885PI4K2A 1006/4885 |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | PI4KA 1991/4885PI4K2B 2891/4885PI4K2A 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.